SLV319

DB05077

small molecule investigational

Deskripsi

SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

839 Data
Cocaine Cocaine may increase the tachycardic activities of SLV319.
Trospium The risk or severity of Tachycardia and drowsiness can be increased when Trospium is combined with SLV319.
Oxyphenonium The risk or severity of Tachycardia and drowsiness can be increased when Oxyphenonium is combined with SLV319.
Benzatropine The risk or severity of Tachycardia and drowsiness can be increased when Benzatropine is combined with SLV319.
Disopyramide The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with SLV319.
Ipratropium The risk or severity of Tachycardia and drowsiness can be increased when Ipratropium is combined with SLV319.
Metixene The risk or severity of Tachycardia and drowsiness can be increased when Metixene is combined with SLV319.
Terfenadine The risk or severity of Tachycardia and drowsiness can be increased when Terfenadine is combined with SLV319.
Buclizine The risk or severity of Tachycardia and drowsiness can be increased when Buclizine is combined with SLV319.
Trihexyphenidyl The risk or severity of Tachycardia and drowsiness can be increased when Trihexyphenidyl is combined with SLV319.
Oxyphencyclimine The risk or severity of Tachycardia and drowsiness can be increased when Oxyphencyclimine is combined with SLV319.
Procyclidine The risk or severity of Tachycardia and drowsiness can be increased when Procyclidine is combined with SLV319.
Profenamine The risk or severity of Tachycardia and drowsiness can be increased when Profenamine is combined with SLV319.
Hyoscyamine The risk or severity of Tachycardia and drowsiness can be increased when Hyoscyamine is combined with SLV319.
Methscopolamine bromide The risk or severity of Tachycardia and drowsiness can be increased when Methscopolamine bromide is combined with SLV319.
Darifenacin The risk or severity of Tachycardia and drowsiness can be increased when Darifenacin is combined with SLV319.
Tridihexethyl The risk or severity of Tachycardia and drowsiness can be increased when Tridihexethyl is combined with SLV319.
Anisotropine methylbromide The risk or severity of Tachycardia and drowsiness can be increased when Anisotropine methylbromide is combined with SLV319.
Atropine The risk or severity of Tachycardia and drowsiness can be increased when Atropine is combined with SLV319.
Nicardipine The risk or severity of Tachycardia and drowsiness can be increased when Nicardipine is combined with SLV319.
Pirenzepine The risk or severity of Tachycardia and drowsiness can be increased when Pirenzepine is combined with SLV319.
Homatropine methylbromide The risk or severity of Tachycardia and drowsiness can be increased when Homatropine methylbromide is combined with SLV319.
Benzquinamide The risk or severity of Tachycardia and drowsiness can be increased when Benzquinamide is combined with SLV319.
Propantheline The risk or severity of Tachycardia and drowsiness can be increased when Propantheline is combined with SLV319.
Dicyclomine The risk or severity of Tachycardia and drowsiness can be increased when Dicyclomine is combined with SLV319.
Biperiden The risk or severity of Tachycardia and drowsiness can be increased when Biperiden is combined with SLV319.
Quinidine The risk or severity of Tachycardia and drowsiness can be increased when Quinidine is combined with SLV319.
Methantheline The risk or severity of Tachycardia and drowsiness can be increased when Methantheline is combined with SLV319.
Cycrimine The risk or severity of Tachycardia and drowsiness can be increased when Cycrimine is combined with SLV319.
Glycopyrronium The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with SLV319.
Tolterodine The risk or severity of Tachycardia and drowsiness can be increased when Tolterodine is combined with SLV319.
Oxybutynin The risk or severity of Tachycardia and drowsiness can be increased when Oxybutynin is combined with SLV319.
Flavoxate The risk or severity of Tachycardia and drowsiness can be increased when Flavoxate is combined with SLV319.
Diphenidol The risk or severity of Tachycardia and drowsiness can be increased when Diphenidol is combined with SLV319.
Tiotropium The risk or severity of Tachycardia and drowsiness can be increased when Tiotropium is combined with SLV319.
Solifenacin The risk or severity of Tachycardia and drowsiness can be increased when Solifenacin is combined with SLV319.
Isopropamide The risk or severity of Tachycardia and drowsiness can be increased when Isopropamide is combined with SLV319.
Mepenzolate The risk or severity of Tachycardia and drowsiness can be increased when Mepenzolate is combined with SLV319.
Fesoterodine The risk or severity of Tachycardia and drowsiness can be increased when Fesoterodine is combined with SLV319.
Hexocyclium The risk or severity of Tachycardia and drowsiness can be increased when Hexocyclium is combined with SLV319.
Dimetindene The risk or severity of Tachycardia and drowsiness can be increased when Dimetindene is combined with SLV319.
Aclidinium The risk or severity of Tachycardia and drowsiness can be increased when Aclidinium is combined with SLV319.
Dexetimide The risk or severity of Tachycardia and drowsiness can be increased when Dexetimide is combined with SLV319.
Umeclidinium The risk or severity of Tachycardia and drowsiness can be increased when Umeclidinium is combined with SLV319.
Trimebutine The risk or severity of Tachycardia and drowsiness can be increased when Trimebutine is combined with SLV319.
Imidafenacin The risk or severity of Tachycardia and drowsiness can be increased when Imidafenacin is combined with SLV319.
Butylscopolamine The risk or severity of Tachycardia and drowsiness can be increased when Butylscopolamine is combined with SLV319.
Thonzylamine The risk or severity of Tachycardia and drowsiness can be increased when Thonzylamine is combined with SLV319.
Methscopolamine The risk or severity of Tachycardia and drowsiness can be increased when Methscopolamine is combined with SLV319.
Revefenacin The risk or severity of Tachycardia and drowsiness can be increased when Revefenacin is combined with SLV319.
Oxitropium The risk or severity of Tachycardia and drowsiness can be increased when Oxitropium is combined with SLV319.
Propiverine The risk or severity of Tachycardia and drowsiness can be increased when Propiverine is combined with SLV319.
Batefenterol The risk or severity of Tachycardia and drowsiness can be increased when Batefenterol is combined with SLV319.
Mebeverine The risk or severity of Tachycardia and drowsiness can be increased when Mebeverine is combined with SLV319.
Tropatepine The risk or severity of Tachycardia and drowsiness can be increased when Tropatepine is combined with SLV319.
Prifinium The risk or severity of Tachycardia and drowsiness can be increased when Prifinium is combined with SLV319.
Piperidolate The risk or severity of Tachycardia and drowsiness can be increased when Piperidolate is combined with SLV319.
Benzilone The risk or severity of Tachycardia and drowsiness can be increased when Benzilone is combined with SLV319.
Difemerine The risk or severity of Tachycardia and drowsiness can be increased when Difemerine is combined with SLV319.
Phenglutarimide The risk or severity of Tachycardia and drowsiness can be increased when Phenglutarimide is combined with SLV319.
Mazaticol The risk or severity of Tachycardia and drowsiness can be increased when Mazaticol is combined with SLV319.
Etybenzatropine The risk or severity of Tachycardia and drowsiness can be increased when Etybenzatropine is combined with SLV319.
Otilonium The risk or severity of Tachycardia and drowsiness can be increased when Otilonium is combined with SLV319.
Poldine The risk or severity of Tachycardia and drowsiness can be increased when Poldine is combined with SLV319.
Bevonium The risk or severity of Tachycardia and drowsiness can be increased when Bevonium is combined with SLV319.
Rociverine The risk or severity of Tachycardia and drowsiness can be increased when Rociverine is combined with SLV319.
Bornaprine The risk or severity of Tachycardia and drowsiness can be increased when Bornaprine is combined with SLV319.
Etanautine The risk or severity of Tachycardia and drowsiness can be increased when Etanautine is combined with SLV319.
Tiemonium iodide The risk or severity of Tachycardia and drowsiness can be increased when Tiemonium iodide is combined with SLV319.
Dihexyverine The risk or severity of Tachycardia and drowsiness can be increased when Dihexyverine is combined with SLV319.
Penthienate The risk or severity of Tachycardia and drowsiness can be increased when Penthienate is combined with SLV319.
Diphemanil The risk or severity of Tachycardia and drowsiness can be increased when Diphemanil is combined with SLV319.
Camylofin The risk or severity of Tachycardia and drowsiness can be increased when Camylofin is combined with SLV319.
Fenpiverinium The risk or severity of Tachycardia and drowsiness can be increased when Fenpiverinium is combined with SLV319.
Emetonium iodide The risk or severity of Tachycardia and drowsiness can be increased when Emetonium iodide is combined with SLV319.
Pipenzolate The risk or severity of Tachycardia and drowsiness can be increased when Pipenzolate is combined with SLV319.
Timepidium The risk or severity of Tachycardia and drowsiness can be increased when Timepidium is combined with SLV319.
Chlorphenoxamine The risk or severity of Tachycardia and drowsiness can be increased when Chlorphenoxamine is combined with SLV319.
Phentermine The risk or severity of Tachycardia can be increased when SLV319 is combined with Phentermine.
Midodrine The risk or severity of Tachycardia can be increased when SLV319 is combined with Midodrine.
Norepinephrine The risk or severity of Tachycardia can be increased when SLV319 is combined with Norepinephrine.
Phenylephrine The risk or severity of Tachycardia can be increased when SLV319 is combined with Phenylephrine.
Phenylpropanolamine The risk or severity of Tachycardia can be increased when SLV319 is combined with Phenylpropanolamine.
Labetalol The risk or severity of Tachycardia can be increased when SLV319 is combined with Labetalol.
Metaraminol The risk or severity of Tachycardia can be increased when SLV319 is combined with Metaraminol.
Epinephrine The risk or severity of Tachycardia can be increased when SLV319 is combined with Epinephrine.
Methoxamine The risk or severity of Tachycardia can be increased when SLV319 is combined with Methoxamine.
Orciprenaline The risk or severity of Tachycardia can be increased when SLV319 is combined with Orciprenaline.
Phenmetrazine The risk or severity of Tachycardia can be increased when SLV319 is combined with Phenmetrazine.
Dobutamine The risk or severity of Tachycardia can be increased when SLV319 is combined with Dobutamine.
Pseudoephedrine The risk or severity of Tachycardia can be increased when SLV319 is combined with Pseudoephedrine.
Ritodrine The risk or severity of Tachycardia can be increased when SLV319 is combined with Ritodrine.
Terbutaline The risk or severity of Tachycardia can be increased when SLV319 is combined with Terbutaline.
Oxymetazoline The risk or severity of Tachycardia can be increased when SLV319 is combined with Oxymetazoline.
Dopamine The risk or severity of Tachycardia can be increased when SLV319 is combined with Dopamine.
Isoprenaline The risk or severity of Tachycardia can be increased when SLV319 is combined with Isoprenaline.
Acebutolol The risk or severity of Tachycardia can be increased when SLV319 is combined with Acebutolol.
Lisdexamfetamine The risk or severity of Tachycardia can be increased when SLV319 is combined with Lisdexamfetamine.
Fenoterol The risk or severity of Tachycardia can be increased when SLV319 is combined with Fenoterol.
Ephedrine The risk or severity of Tachycardia can be increased when SLV319 is combined with Ephedrine.

Target Protein

Cannabinoid receptor 1 CNR1

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul